Compare Hinge Health Inc. Class A Common Stock (HNGE) vs Oklo Inc (OKLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hinge Health Inc. Class A Common Stock vs Oklo Inc — how do they compare? Hinge Health Inc. Class A Common Stock trades at $104.95 (market cap $8.48B), while Oklo Inc trades at $28.56 (market cap $5.91B). The key difference: Hinge Health Inc. Class A Common Stock is the larger of the two by market cap, and Hinge Health Inc. Class A Common Stock is trading nearer its 52-week high, Oklo Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Hinge Health Inc. Class A Common Stock for 0 Days and Oklo Inc for 33 Days on average.
| HNGE | OKLO | |
|---|---|---|
Market Cap | $8.48B | $5.91B |
Volume | 879,799 | 8,898,651 |
Sector | Health | Utilities |
52-Week High | $105.14 | $171.56 |
52-Week Low | $31.17 | $29.04 |
Typical Hold Time | 0 Days | 33 Days |
Enterprise Value | $8.10B | $3.45B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
OKLO trades at $31.78, down 1.33% on the day, with a bearish technical signal despite oversold RSI readings. The company shows no revenue in 2025 and a net loss of $105.66 million, with negative profit margins and ROE. Recent news highlights competition in the nuclear sector and OKLO's $1 billion stock sale, while analyst consensus remains strongly bullish with a $78.63 price target.
OKLO presents high-risk, high-reward potential as an early-stage nuclear company. The bullish analyst outlook and strategic project pipeline offer upside, but significant execution risks, cash burn, and competitive pressures require careful consideration. Investor sentiment is mixed amid operational challenges and dilution concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →About Oklo Inc
Oklo Inc. is a company focused on developing and commercializing advanced fission power plants. The company specializes in micro-reactor technology, specifically the Aurora design, which uses advanced fuel to produce reliable, clean, and cost-competitive power. Oklo aims to provide scalable, on-site power solutions to various customers, including remote communities, industrial facilities, and government entities, positioning itself as an innovator in the next generation of nuclear energy.
Read more on OKLO →
